Health Canada has given its approval to the new antiepileptic drug Vimpat from
. The treatment represents a potential benefit to sufferers of epilepsy and a toehold in the neurological treatment field for Oakville biopharmaceutical company UCB
The Oakville office, the Canadian branch of international pharmaceutical giant UCB, had previously had a treatment for immunology, according to Business Unit Director Ross Glover, "This is a big milestone for the company — this is the first of several neurological treatments we intend to bring to the Canadian market."
The company's Canadian office was launched in 2006, Glover says, with the dual goals of bringing UCB's global therapies to the Canadian market and to do homegrown research that would "bring the benefit of our Canadian neurologists to the global platform." In its four years, the company has grown to employ 28 staff in the GTA.
This approval will of course, Glover says, mean growth for the company, and he anticipates further growth in step with research outcomes. "As far as employment goes, I expect ongoing hiring for the next five years as we go forward and as we have success."
Writer: Edward Keenan
Source: Ross Glover, UCB Canada Inc.